NCT01297166 is a Phase 1 clinical trial of LEO 27989 ointment in Psoriasis Vulgaris, sponsored by LEO Pharma.

Who is sponsoring NCT01297166?

NCT01297166 is sponsored by LEO Pharma.

What drugs are being tested in NCT01297166?

Interventions in NCT01297166: LEO 27989 ointment, Calcipotriol plus LEO 27989 ointment, Calcipotriol ointment, Vehicle ointment.

What condition does NCT01297166 study?

NCT01297166 studies Psoriasis Vulgaris.

Is NCT01297166 still recruiting?

NCT01297166 is currently completed. Last updated 21 February 2025.

Last reviewed 2025-02-21 · How we verify

NCT01297166

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris.

Completed Phase 1 Last updated 21 February 2025

What this trial tests

Phase 1 trial testing LEO 27989 ointment in Psoriasis Vulgaris in 25 participants. Completed in 1 April 2011.

Timeline

1 February 2011

Primary endpoint
1 April 2011

1 April 2011

Quick facts

Lead sponsor	LEO Pharma
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	25
Start date	1 February 2011
Primary completion	1 April 2011
Estimated completion	1 April 2011
Sites	1 location across France

Drugs / interventions tested

LEO 27989 ointment — full drug profile →
Calcipotriol plus LEO 27989 ointment — full drug profile →
Calcipotriol ointment
Vehicle ointment

Conditions studied

Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →

Sponsor

LEO Pharma — full company profile →

Who can join

18 and older, any sex, with Psoriasis Vulgaris. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Absolute change in Total Clinical Score (TCS) of clinical symptoms (sum of erythema, scaling and infiltration) at end of treatment compared to baseline.
Time frame: 3 weeks
TCS range from 0 (all symptoms absent) to 9 (all symptoms severe)

Sponsor's own description

The purpose of this study is to evaluate the anti-psoriatic effect of LEO 27989 ointment and calcipotriol plus LEO 27989 ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Psoriasis Vulgaris

Currently open trials in the same condition.

NCT07426120 — Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III · Phase 3 · recruiting
NCT07320872 — Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris · recruiting
NCT06398106 — Proactive TDM Versus Standard Use of Biologics in Psoriasis · Phase 4 · recruiting
NCT05185258 — Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study · Phase 4 · active not recruiting
NCT04950218 — Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis · recruiting

Other LEO Pharma trials

Trials by the same sponsor.

NCT07335588 — A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus · Phase 3 · not yet recruiting
NCT07013201 — A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to · Phase 2 · recruiting
NCT06444867 — A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 15896 · Phase 1 · completed
NCT06311682 — A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and · Phase 3 · recruiting
NCT05923099 — A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic De · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01297166 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LEO Pharma
Last refreshed: 21 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01297166.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing